China Healthcare Summit - Award Winners
For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. In 2021, BayHelix and BioCentury will jointly host the 8th China Healthcare Summit (Nov. 16-19, Grand Hyatt Shanghai + Digital), and will present the awards in seven categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; COVID-19 Social Responsibility Initiatives (Company; Person) of the Year; Person of the Year; and Woman Leader of the Year. Congratulations to the 2020 BayHelix Award Winners listed below.
CONGRATULATIONS TO ALL THE 2020 AWARD WINNERS
R&D Achievement of the Year | Junshi Biosciences, CAS Institute of Microbiology
R&D Achievement of the Year, recognizing a scientific discovery in China with direct impact to drug and/or MedTech R&D or a significant achievement in pharmaceutical and/or MedTech development milestones.
Junshi Biosciences, CAS Institute of Microbiology
SARS-CoV-2 neutralizing monoclonal antibody (JS016). The first COVID-19 mAb to enter the clinic in China and the first globally to enter the clinic in healthy volunteers.
Deal of the Year | I-Mab and AbbVie
Deal of the Year, recognizing a groundbreaking pharmaceutical and/or MedTech fund-raising, collaboration, technology transfer, licensing, M&A or joint venture that involves a Chinese entity, either within China or cross-border.
I-Mab and AbbVie
Global collaboration for development and commercialization of lemzoparlimab, an anti-CD47 mAb discovered by I-Mab. I-Mab received $180M upfront (plus $20M milestone) for ex-China rights. It is eligible for $1.7B in milestones including $840M tied to development and regulatory events.
Commercial Achievement of the Year | Jiangsu Hengrui Medicine
Commercial Achievement of the Year, recognizing a creative model that delivered superior value to patients/payers in China and commercial success.
Jiangsu Hengrui Medicine
Anti-PD-1 antibody camrelizumab (SHR-1210) approved in 2020 in China for three large patient indications, including 1st line non-small cell lung cancer (NSCLC), 2nd line hepatocellular carcinoma (HCC) and 2nd line esophageal squamous cell carcinoma (ESCC).
Company of the Year | Innovent Biologics
Company of the Year, recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, MedTech and/or healthcare industry.
Established in 2011, Innovent has built a pipeline of 23 compounds. In 2020, it formed several global partnerships, including out-licensing ex-China rights to its anti-PD-1 to Eli Lilly, and in-licensing Roche’s drug development platform.
Person of the Year | Charles Li
Person of the Year, recognizing an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem for drug and/or MedTech R&D, deal transactions, and/or commercialization etc. in China.
As Executive Director & CEO of HKEX, Charles led development and launch of Chapter 18A, ushering in a new era for China biotech and its investors. Chapter 18A allowed pre-revenue biotechs to list for the first time on HKEX, providing capital to China’s growing biotech industry and a path to exit for investors.
Woman Leader of the Year | Samantha Du
Woman Leader of the Year, recognizing an outstanding female leader whose contributions have changed the landscape, reputation and ecosystem for biopharma or MedTech in China.
Samantha has successfully led rapid growth and expansion of Zai Lab in 2020, making Zai Lab one of the most valued biotech companies in China. For many years she has been an inspiring role model to woman leaders – and to future leaders – in the China life sciences community.
COVID-19 Social Responsibility Initiative (company) | Zenni Optical
COVID-19 Social Responsibility Initiative (company), recognizing an outstanding contribution to the global fight against COVID-19.
COVID-19 Social Responsibility Initiative (persons) | Ying Yang and Victor Shi
COVID-19 Social Responsibility Initiative (persons), recognizing an outstanding contribution to the global fight against COVID-19.
Ying Yang and Victor Shi
For a list of last year’s winners, please visit the 2019 China Summit web page here.